SAN DIEGO, March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2022.
Read more at prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here